IMMX Stock — Immix Biopharma Inc.: Cash, EV, Pipeline

What they do

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (“CAR-T”) in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201 (“NXC-201”), currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a NEXICART-1 (NCT04720313) clinical trial.

Source: 10-K FY2025 via SEC EDGAR

Share price

$8.06

Market cap

$668.2M

Cash

$234.2M

Enterprise value

$434.0M

Balance sheet

Cash	$234.2M
Debt	$0.0M
Net cash	$234.2M
Enterprise value	$434.0M
Basic shares	71.5M shares
Fully diluted shares	80.8M shares
Fully diluted market cap	$651.1M
Cash per share	$3.27
Quarterly burn	$11.7M
Cash runway	20.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

71.5M

Pre-funded warrants

2.4M

Options

3.9M

RSUs

0.0M

Warrants

2.9M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

80.8M

Cap table as of 2026-06-30.

Price history

Loading IMMX daily closes…

Loading price history…

Next catalyst

NXC-201 CAR-T · Jan 12 - Feb 23 in 9 wks · Phase 2 · Light Chain (AL) Amyloidosis

Recently reported

NXC-201 Mixed · 2026-09-29

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 9 wks	NXC-201 CAR-T	Phase 2	Light Chain (AL) Amyloidosis	September 2026 end of March 2027
Jan 12 - Feb 23 in 27 mo	NXC-201	Phase 3	Light Chain (AL) Amyloidosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NXC-201

Phase 2 · Active Modality: CAR-T cell therapy

Target BCMA

Partnerships Hadasit Medical Research / BIRAD (Dec 2022; $1.5M upfront, up to $4.5M development milestones, $10M Phase III initiation, $13.5M first commercial sale, up to $20M net sales milestones); patent license with U.S. medical research foundation (Aug 2024)

Indications

Relapsed/refractory AL amyloidosis (Phase 2)

Catalysts

— December 2025

Status note Lead candidate; Phase 1b/2 NEXICART-2 (U.S., relapsed/refractory AL amyloidosis) ongoing with 40-patient target; ex-U.S. Phase 1b/2a NEXICART-1 also ongoing. Company plans randomized Phase 3 in newly diagnosed AL amyloidosis with final readout and BLA to follow; filing also cites NXC-201 for select other serious diseases (unspecified).

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07709715	Phase 3	Not yet recruiting	Collaborator	Nexcella Inc.	—	Light Chain (AL) Amyloidosis	—
NCT06097832	Phase 2	Active, not recruiting	Collaborator	Nexcella Inc.	—	Light Chain (AL) Amyloidosis	September 2026 end of March 2027

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Nexcella Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Great Point Partners	1,277,642	+927,642	3.10%	2026-08-14
Logos Global Management	1,000,000	-225,000	0.44%	2026-08-14
Sphera Biotech	270,000	+270,000	0.40%	2026-08-14
ADAR1 Capital Management	0	-10,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

IMMX — Immix Biopharma Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

IMMX — Immix Biopharma Inc.